“Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s616. https://doi.org/10.25251/n1p8w126.